

Technical Alert

Roche 6800 SARS-CoV-2 (COVID-19) Supply Shortage

TO: Medical Staff and Clients

FROM: Dr. Wesley Kim, MD

Medical Director, DLS and QMC West

Dr. Amy Woron, PhD Dr. A. Christian Whelen, PhD Dr. Ana Ortega-Lopez, MD

Manager, DLS Molecular VP & Technical Director Medical Director QMC Punchbowl,

Microbiology & Molecular North Hawaii and Molokai

DATE: July 8, 2020

SUBJECT: Supply shortage triggers send-out testing for non-priority SARS-CoV-2 requests

Surges in demand for testing supplies on the U.S. mainland has constrained the allocation for our main high throughput testing platform. Roche has cut back our supplies for the SARS-CoV-2 assay in the Roche 6800 to less than half of present demand. Roche provided this notification Monday, July 6, 2020 at about 5:00 pm.

This reduces DLS Central capacity from 550+ per day to between 125 and 250 per day. This necessitates utilization of other local labs and mainland reference laboratories for overflow testing.

Effective 6:00 pm on July 6, send out testing resumed for non-priority SARS-COV-2 (COVID-19). The normal turn around time (TAT) for mainland testing is 3-5 days; however, both reference labs report backlogs. This will remain in effect until stable resupply is established.

Priority testing will remain on-island, but expect longer TAT. Recent TAT has been stable at same or next day. Anticipate this to increase by 24-72 hours.

Please categorize specimens appropriately.

- Identify priority specimens in CareLink or with a priority flag (contact your DLS representative for more information).
- Only flag priority specimens as a priority.
- Non-medical testing (travel, return to school/work, employee screens, etc.) are NOT priority specimens.

We apologize for this inconvenience, and are working closely with Roche to resolve the supply shortage. They are increasing their manufacturing capacity, but acknowledge it may be several months before production is increased.

Please refer any questions to DLS Client Services at 589-5101.